News

Risankizumab outperformed ustekinumab in rates of clinical remission at week 24 and rates of endoscopic remission at week 48, meeting both primary endpoints of the phase 3 trial.

On September 12, 2023, the FDA announced it had issued warning letters to 8 companies, including CVS Health and Walgreens, for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law.

This new research indicates that children with ARDS surviving discharge have a higher probability of readmission than was reported previously among the pediatric intensive care unit population.

An analysis of data from more than 60,000 women details associations between specific chronotypes and risk of unhealthy lifestyle behaviors as well as risk of developing type 2 diabetes.

Results from a cross-sectional analysis of NHANES data found a short sleep duration was associated with an increased risk of early AMD.

Investigators called attention to low patient-reported levels of clinician recommendation for colorectal cancer screening during wellness visits, noting the prevalence was lowest among those without insurance and without a usual source of care.

The agency anticipates the decision to update monovalent formulas of the Pfizer, Moderna, and future COVID-19 vaccines to reflect circulating variants will become an annual practice.

Crinetics announced findings from the PATHFNDR-1 trial showing the investigative oral daily drug may provide patients with the rare disease an alternative from recurring injection therapy.

New data suggest patients with nAMD on prior anti-VEGF therapy experienced improved visual acuity and macular OCT parameters after switching to faricimab.

An analysis of data from more than 20,000 women in the New York City A1c registry details the prevalence of and drivers behind racial/ethnic disparities in the incidence of type 2 diabetes following gestational diabetes mellitus.

Findings from two recent studies provide insight into the association between anti-VEGF treatment for retinal diseases and the risk of kidney injury.

At ERS International Congress 2023, new data related to use of sotatercept offered providers additional insight into the effects of the agent in people with PAH.

Results from the study found independent associations between handgrip strength, abPG-SGA, and SaskIBD-NRT with risk of IBD-related hospitalization, further noting clinical frailty scale and subjective global assessment were not associated with risk of hospitalization.

Investigators noted improved liver function, increased prevalence of anemia, and decreased hemoglobin concentration, hematocrit index, and estimated glomerular filtration rate among patients with HCV after 12 weeks of DAA treatment.

Stephen Ziegler, PhD, JD, discusses the challenges cannabis treatment presents as a form of complementary therapy for rheumatic disease.

Stephen Ziegler, PhD, JD, describes the various alternative and complementary treatments available for palliative care and pain management in patients with rheumatic disease.

Stephen Ziegler, PhD, JD, explains pain management and prescribing opioid medications in the wake of Ruan v United States.

Elizabeth Volkmann, MD, MS, explains the current treatment options available for SSc-ILD and how to evaluate and manage this patient population.

Elizabeth Volkmann, MD, MS, discusses systemic sclerosis associated interstitial lung disease and how to evaluate subclinical, clinical, and progressive disease for the best outcome.

The new data addressed the lack of studies examining melanoma incidence despite the existence of research examining increases in relative numbers of advanced melanomas during the pandemic.

A cross-sectional analysis of Medicare Part B data spending shows ophthalmologists who received manufacturer funding were less likely to prescribe bevacizumab.

Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and managing director of Opthea Limited, to discuss sozinibercept, a novel recombinant “trap” fusion protein targeting inhibition of VEGF-C and VEGF-D.

New 3-year analysis shows a significant rate of patients were able to avoid relapse or hospitalization while receiving the long-acting injectable.

This research was the result of the first study assessing adaptive smoking cessation treatment within a clinical population using very few criteria for exclusion.

Results from a secondary analysis of PALADIN showed the 0.19-mg implant was associated with mostly stable IOPs in eyes with DME over a 36-month period.

Results from RESPONSE show seladelpar may improve measures of disease activity and reduce symptom burden in patients with PBC.

This case report from Brady Pregerson, MD, features a man in his early-30s with chest pain, dizziness, and shortness of breath. Check out the ECG and determine the correct diagnosis!

Performance metrics of NIS4, the ELF test, and FibroMeter VCTE met prespecified criteria for qualification for regulatory approval in stage 1 of the NIMBLE project's circulating biomarker workstream.